These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 30842749)
1. Chronic Myeloid Leukemia Patient's Voice About the Experience of Treatment-Free Remission Failure: Results From the Italian Sub-Study of ENESTPath Exploring the Emotional Experience of Patients During Different Phases of a Clinical Trial. Borghi L; Galimberti S; Baratè C; Bonifacio M; Capochiani E; Cuneo A; Falzetti F; Iurlo A; Lunghi F; Minotto C; Orlandi EM; Rege-Cambrin G; Sica S; Supekar S; Haenig J; Vegni E Front Psychol; 2019; 10():329. PubMed ID: 30842749 [No Abstract] [Full Text] [Related]
2. Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy. Borghi L; Rosti G; Maggi A; Breccia M; Di Bona E; Iurlo A; La Barba G; Sportoletti P; Albano F; Galimberti S; Rivellini F; Cambrin GR; Capodanno I; Cuneo A; Bonifacio M; Sica S; Arcaini L; Capochiani E; Minotto C; Ciceri F; Crugnola M; Di Caprio L; Supekar S; Elena C; Baccarani M; Vegni E Front Oncol; 2021; 11():638689. PubMed ID: 34123791 [TBL] [Abstract][Full Text] [Related]
3. Budget impact analysis of treatment-free remission in nilotinib-treated Japanese chronic myeloid leukemia patients. Yamazaki K; Inagaki N; Moldaver D; Viana R; Kimura S Cancer Sci; 2020 Jul; 111(7):2526-2535. PubMed ID: 32324296 [TBL] [Abstract][Full Text] [Related]
4. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study. Mahon FX; Boquimpani C; Kim DW; Benyamini N; Clementino NCD; Shuvaev V; Ailawadhi S; Lipton JH; Turkina AG; De Paz R; Moiraghi B; Nicolini FE; Dengler J; Sacha T; Takahashi N; Fellague-Chebra R; Acharya S; Wong S; Jin Y; Hughes TP Ann Intern Med; 2018 Apr; 168(7):461-470. PubMed ID: 29459949 [TBL] [Abstract][Full Text] [Related]
5. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. Ross DM; Masszi T; Gómez Casares MT; Hellmann A; Stentoft J; Conneally E; Garcia-Gutierrez V; Gattermann N; le Coutre PD; Martino B; Saussele S; Giles FJ; Radich JP; Saglio G; Deng W; Krunic N; Bédoucha V; Gopalakrishna P; Hochhaus A J Cancer Res Clin Oncol; 2018 May; 144(5):945-954. PubMed ID: 29468438 [TBL] [Abstract][Full Text] [Related]
6. Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26 Pacelli P; Santoni A; Sicuranza A; Abruzzese E; Giai V; Crugnola M; Annunziata M; Galimberti S; Iurlo A; Luciano L; Sorà F; Fava C; Bestoso E; Marzano C; Cartocci A; Defina M; Sammartano V; Cencini E; Raspadori D; Bocchia M Front Pharmacol; 2023; 14():1194712. PubMed ID: 37305536 [No Abstract] [Full Text] [Related]
7. Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia. Han JJ Blood Res; 2023 Apr; 58(S1):S58-S65. PubMed ID: 37026381 [TBL] [Abstract][Full Text] [Related]
8. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. Radich JP; Hochhaus A; Masszi T; Hellmann A; Stentoft J; Casares MTG; García-Gutiérrez JV; Conneally E; le Coutre PD; Gattermann N; Martino B; Saussele S; Giles FJ; Ross DM; Aimone P; Li S; Titorenko K; Saglio G Leukemia; 2021 May; 35(5):1344-1355. PubMed ID: 33707652 [TBL] [Abstract][Full Text] [Related]
9. Budget Impact of Treatment-Free Remission in Treating Chronic-Phase Philadelphia-Positive Chronic Myeloid Leukemia in Lebanon. Elias F; Gebran A; Said C; Beker RV; Ammar W J Glob Oncol; 2019 Jun; 5():1-7. PubMed ID: 31166826 [TBL] [Abstract][Full Text] [Related]
10. A Systematic Review on Second Treatment-Free Remission (TFR) Attempt in Chronic Myeloid Leukemia (CML): Can it be Applied in Clinical Practice? Çiftçiler R; Akın MG; Erat Z; Eşkazan AE Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):8-14. PubMed ID: 36344420 [TBL] [Abstract][Full Text] [Related]
11. Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey. Lou J; Huang J; Wang Z; Wen B; Tu C; Huang W; Zhai Z; Du X Patient Prefer Adherence; 2018; 12():1025-1032. PubMed ID: 29942119 [TBL] [Abstract][Full Text] [Related]
12. Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient-Physician Perspective. Saglio G; Sharf G; Almeida A; Bogdanovic A; Bombaci F; Čugurović J; Deekes N; Garcia-Gutiérrez V; de Jong J; Narbutas Š; Westerweel P; Zackova D Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):375-379. PubMed ID: 29753691 [TBL] [Abstract][Full Text] [Related]
13. Treatment-Free Remission in Chronic Myeloid Leukemia: Can We Identify Prognostic Factors? Saifullah HH; Lucas CM Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439327 [TBL] [Abstract][Full Text] [Related]
14. Failure of treatment-free remission after a prolonged deep molecular response in patients with chronic myeloid leukemia. Nasnas PE; Jabbour EJ; Sasaki K; Issa GC; Masarova L; Short NJ; Haddad FG Acta Haematol; 2024 Apr; ():. PubMed ID: 38574468 [TBL] [Abstract][Full Text] [Related]
15. Regulatory T Cell as a Biomarker of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia. Fujioka Y; Sugiyama D; Matsumura I; Minami Y; Miura M; Atsuta Y; Ohtake S; Kiyoi H; Miyazaki Y; Nishikawa H; Takahashi N Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885012 [TBL] [Abstract][Full Text] [Related]
16. Recovering from chronic myeloid leukemia: the patients' perspective seen through the lens of narrative medicine. Graffigna G; Cecchini I; Breccia M; Capochiani E; Della Seta R; Galimberti S; Melosi A; Simonetti F; Pizzuti M; Capalbo SF; Falzetti F; Mazza P; Di Renzo N; Mastrullo L; Rapezzi D; Orlandi E; Intermesoli T; Iurlo A; Pungolino E; Pacilli M Qual Life Res; 2017 Oct; 26(10):2739-2754. PubMed ID: 28608152 [TBL] [Abstract][Full Text] [Related]
17. Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update. Hughes TP; Clementino NCD; Fominykh M; Lipton JH; Turkina AG; Moiraghi EB; Nicolini FE; Takahashi N; Sacha T; Kim DW; Fellague-Chebra R; Tiwari R; Bouard C; Mahon FX Leukemia; 2021 Jun; 35(6):1631-1642. PubMed ID: 33980976 [TBL] [Abstract][Full Text] [Related]
18. Treatment-free remission of chronic myeloid leukemia in real-world practice by the detection limit of MR4.3. Park S; Choi EJ; Lee H; Jo DY; Jung CW; Kong JH; Kim H; Leuk Res; 2021 Jun; 105():106578. PubMed ID: 33892341 [TBL] [Abstract][Full Text] [Related]
19. Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia. Breccia M; Abruzzese E; Annunziata M; Luciano L; Sica S Front Oncol; 2021; 11():631570. PubMed ID: 33777785 [TBL] [Abstract][Full Text] [Related]
20. Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study. Iurlo A; Cattaneo D; Artuso S; Consonni D; Abruzzese E; Binotto G; Bocchia M; Bonifacio M; Castagnetti F; Galimberti S; Gozzini A; Iezza M; Latagliata R; Luciano L; Maggi A; Miggiano MC; Pregno P; Rege-Cambrin G; Russo S; Scortechini AR; Tafuri A; Tiribelli M; Fava C; Rosti G; Foa R; Breccia M; Saglio G Front Oncol; 2022; 12():839915. PubMed ID: 35311109 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]